Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams. (May 2016)

• Record Type: Journal Article
• Authors: Carugo, Dario; Ankrett, Dyan N; Zhao, Xuefeng; Zhang, Xunli; Hill, Martyn; O'Byrne, Vincent; Hoad, James; Arif, Mehreen; Wright, David DI; Lewis, Andrew L
• Is Part Of: Phlebology. Volume 31:Number 4(2016)
• Page Start: 283
• Page End: 295
• Publication Date: 2016-05
• Subjects: Foam drainage times -- foam half time -- physician-compounded foams -- bubble size -- bubble size distribution -- varicose veins -- polidocanol endovenous microfoam -- sclerotherapy -- biomimetic analysis method -- polidocanol injectable foam; Veins -- Diseases -- Periodicals; 616.14
• DOI: 10.1177/0268355515589063
• Languages: English
• ISSNs: 0268-3555

Abstract

Objective: To compare foam bubble size and bubble size distribution, stability, and degradation rate of commercially available polidocanol endovenous microfoam (Varithena®) and physician-compounded foams using a number of laboratory tests. Methods: Foam properties of polidocanol endovenous microfoam and physician-compounded foams were measured and compared using a glass-plate method and a Sympatec QICPIC image analysis method to measure bubble size and bubble size distribution, Turbiscan™ LAB for foam half time and drainage and a novel biomimetic vein model to measure foam stability. Physician-compounded foams composed of polidocanol and room air, CO2, or mixtures of oxygen and carbon dioxide (O2 :CO2 ) were generated by different methods. Results: Polidocanol endovenous microfoam was found to have a narrow bubble size distribution with no large (>500 µm) bubbles. Physician-compounded foams made with the Tessari method had broader bubble size distribution and large bubbles, which have an impact on foam stability. Polidocanol endovenous microfoam had a lower degradation rate than any physician-compounded foams, including foams made using room air (p < 0.035). The same result was obtained at different liquid to gas ratios (1:4 and 1:7) for physician-compounded foams. In all tests performed, CO2 foams were the least stable and different O2 :CO2 mixtures had intermediate performance. In the biomimetic vein model, polidocanol endovenous microfoam had the slowest degradation rate and longest calculated dwell time, which represents the length of time the foam is in contact with the vein, almost twice that of physician-compounded foams using room air and eight times better than physician-compounded foams prepared using equivalent gas mixes. Conclusion: Bubble size, bubble size distribution and stability of various sclerosing foam formulations show that polidocanol endovenous microfoam results in better overall performance compared with physician-compounded foams. Polidocanol endovenous microfoam offers better stability and cohesive properties in a biomimetic vein model compared to physician-compounded foams. Polidocanol endovenous microfoam, which is indicated in the United States for treatment of great saphenous vein system incompetence, provides clinicians with a consistent product with enhanced handling properties.